NPC1L1 | NPC1-like 1 | FDA approved drug targets Predicted membrane proteins
| | | | | Group enriched |
OTOP3 | Otopetrin 3 | Predicted membrane proteins
| | | | | Tissue enriched |
PCK2 | Phosphoenolpyruvate carboxykinase 2 (mitochondrial) | Citric acid cycle related proteins Disease related genes Enzymes Mitochondrial proteins Plasma proteins Potential drug targets
| | | | | Group enriched |
PDX1 | Pancreatic and duodenal homeobox 1 | Disease related genes Transcription factors
| | | | | Tissue enriched |
SLC15A1 | Solute carrier family 15 (oligopeptide transporter), member 1 | Predicted membrane proteins Transporters
| | | | | Group enriched |
SLC23A3 | Solute carrier family 23, member 3 | Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Group enriched |
SLC26A3 | Solute carrier family 26 (anion exchanger), member 3 | Cancer-related genes Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Group enriched |
SLC9A3 | Solute carrier family 9, subfamily A (NHE3, cation proton antiporter 3), member 3 | Predicted membrane proteins Transporters
| | | | | Group enriched |
SMLR1 | Small leucine-rich protein 1 | Predicted membrane proteins
| | | | | Group enriched |
SPINK4 | Serine peptidase inhibitor, Kazal type 4 | Predicted secreted proteins
| | | | | Group enriched |
SULT1B1 | Sulfotransferase family, cytosolic, 1B, member 1 | Plasma proteins
| | | | | Group enriched |
TMEM132E | Transmembrane protein 132E | Disease related genes Predicted membrane proteins
| | | | | Group enriched |
TMEM253 | Transmembrane protein 253 | Predicted membrane proteins
| | | | | Group enriched |
TRPM6 | Transient receptor potential cation channel, subfamily M, member 6 | Disease related genes Enzymes Plasma proteins Potential drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
UGT2B17 | UDP glucuronosyltransferase 2 family, polypeptide B17 | Enzymes Predicted membrane proteins
| | | | | Group enriched |
VNN1 | Vanin 1 | Enzymes Plasma proteins Predicted secreted proteins
| | | | | Group enriched |
ACY1 | Aminoacylase 1 | Disease related genes Enzymes Plasma proteins Potential drug targets
| | | | | Group enriched |
AMN | Amnion associated transmembrane protein | Disease related genes Predicted membrane proteins
| | | | | Group enriched |
ANPEP | Alanyl (membrane) aminopeptidase | CD markers Enzymes Plasma proteins Predicted membrane proteins
| | | | | Group enriched |
BCL2L15 | BCL2-like 15 | | | | | | Group enriched |
CAPN13 | Calpain 13 | Enzymes
| | | | | Group enriched |
CDX2 | Caudal type homeobox 2 | Cancer-related genes Transcription factors
| | | | | Group enriched |
DEPDC7 | DEP domain containing 7 | | | | | | Group enriched |
DHDH | Dihydrodiol dehydrogenase (dimeric) | Enzymes
| | | | | Group enriched |
ENPEP | Glutamyl aminopeptidase (aminopeptidase A) | CD markers Enzymes Plasma proteins
| | | | | Group enriched |
HTR1D | 5-hydroxytryptamine (serotonin) receptor 1D, G protein-coupled | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Group enriched |
ITLN2 | Intelectin 2 | Predicted secreted proteins
| | | | | Group enriched |
KCNJ3 | Potassium inwardly-rectifying channel, subfamily J, member 3 | Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
MGAM | Maltase-glucoamylase (alpha-glucosidase) | Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Group enriched |
MUC17 | Mucin 17, cell surface associated | Cancer-related genes Predicted membrane proteins Predicted secreted proteins
| | | | | Group enriched |
PIGR | Polymeric immunoglobulin receptor | Cancer-related genes Plasma proteins Predicted membrane proteins
| | | | | Group enriched |
PLCB3 | Phospholipase C, beta 3 (phosphatidylinositol-specific) | Enzymes
| | | | | Group enriched |
PPP1R14D | Protein phosphatase 1, regulatory (inhibitor) subunit 14D | | | | | | Group enriched |
REG4 | Regenerating islet-derived family, member 4 | Predicted secreted proteins
| | | | | Group enriched |
RP11-595B24.2 | Uncharacterized protein | | | | | | Group enriched |
SHD | Src homology 2 domain containing transforming protein D | | | | | | Group enriched |
SST | Somatostatin | Cancer-related genes Plasma proteins Predicted secreted proteins
| | | | | Group enriched |
SULT1A2 | Sulfotransferase family, cytosolic, 1A, phenol-preferring, member 2 | Enzymes
| | | | | Group enriched |
TMEM92 | Transmembrane protein 92 | Predicted membrane proteins
| | | | | Group enriched |
UNC93A | Unc-93 homolog A (C. elegans) | Predicted membrane proteins
| | | | | Group enriched |
USH1C | Usher syndrome 1C (autosomal recessive, severe) | Cancer-related genes Cytoskeleton related proteins Disease related genes
| | | | | Group enriched |
XDH | Xanthine dehydrogenase | Disease related genes Enzymes FDA approved drug targets Plasma proteins
| | | | | Group enriched |
AADAC | Arylacetamide deacetylase | Enzymes
| | | | | Tissue enhanced |
AC012215.1 | Uncharacterized protein | Predicted membrane proteins
| | | | | Tissue enhanced |
AC021218.2 | Uncharacterized protein | | | | | | Tissue enhanced |
ACE2 | Angiotensin I converting enzyme 2 | Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
ACY3 | Aspartoacylase (aminocyclase) 3 | Enzymes
| | | | | Tissue enhanced |
AKR1B10 | Aldo-keto reductase family 1, member B10 (aldose reductase) | | | | | | Tissue enhanced |
AKR1B15 | Aldo-keto reductase family 1, member B15 | | | | | | Tissue enhanced |
AKR7A3 | Aldo-keto reductase family 7, member A3 (aflatoxin aldehyde reductase) | | | | | | Tissue enhanced |